{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:12:55Z","timestamp":1783732375457,"version":"3.55.0"},"reference-count":12,"publisher":"American Academy of Insurance Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Insur Med"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Benzodiazepines are a class of tranquilizers that, like prescription opiates, are commonly subject to abuse. Abusers of benzodiazepines commonly malinger to sustain access to these prescriptions from their health care providers by creating and enhancing medically necessary conditions requiring treatment with benzodiazepines. Such behavior may involve displays of unrelenting extreme anxiety that are resolved only by the administration of benzodiazepines. Typical substance abuse behaviors also include noncompliance with treatment, lack of self-care, and lack\/failure of counseling. Three cases underwritten for life expectancies in legal matters provide insight as to what kinds of benzodiazepine abuse behaviors can arise, given the conditions and resources available. For life underwriters and medical directors, such benzodiazepine abuse behaviors can serve as an underwriting red flag at time of application. Signs and symptoms of additional substance abuse, such as alcohol and prescription opiates, are likely to be found among those who abuse benzodiazepines and can serve as underwriting red flags.<\/jats:p>","DOI":"10.17849\/insm-53-2-1-5.1","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:18:16Z","timestamp":1781608696000},"page":"182-186","source":"Crossref","is-referenced-by-count":0,"title":["Identifying Benzodiazepine Abuse: A Report of 3 Cases"],"prefix":"10.17849","volume":"53","author":[{"given":"Vera F.","family":"Dolan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7324","reference":[{"key":"i-53-2-182-ref01","series-title":"J Insur Med","first-page":"23","article-title":"Narcotic-seeking behavior and self-Injury: A report of three cases","volume":"52","author":"Dolan","year":"2025","unstructured":"Dolan VF. Narcotic-seeking behavior and self-Injury: A report of three cases. J Insur Med. 2025;52:23\u201330. doi: 10.17849\/insm-52-1-23-30.1"},{"key":"i-53-2-182-ref02","series-title":"DGNews","article-title":"FDA requiring labelling changes for benzodiazepines to include risk of abuse, addiction","unstructured":"FDA requiring labelling changes for benzodiazepines to include risk of abuse, addiction. DGNews. 2020-09024."},{"key":"i-53-2-182-ref03","series-title":"Drugs","article-title":"Benefits and liabilities of benzodiazepines and Z-drugs: What we know and what we don\u2019t know","author":"Silberman","year":"2025","unstructured":"Silberman EK. Benefits and liabilities of benzodiazepines and Z-drugs: What we know and what we don\u2019t know. Drugs. 2025. doi: 10.1007\/s40265-025-02261-2"},{"key":"i-53-2-182-ref04","series-title":"Neurol Int","first-page":"594","article-title":"Benzodiazepines: Uses, dangers, and clinical considerations","volume":"13","author":"Edinoff","year":"2021","unstructured":"Edinoff AN,\nNix CA,\nHollier, et al. Benzodiazepines: Uses, dangers, and clinical considerations. Neurol Int. 2021;13:594\u2013607. doi: 10.3390\/neurolint13040059"},{"key":"i-53-2-182-ref05","series-title":"Aust Prescr","first-page":"152","article-title":"Management of benzodiazepine misuse and dependence","volume":"38","author":"Brett","year":"2015","unstructured":"Brett J,\nMurnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38:152\u2013155."},{"key":"i-53-2-182-ref06","series-title":"Am Fam Physician","first-page":"260","article-title":"Benzodiazepine use disorder: Common questions and answers","volume":"108","author":"Robertson","year":"2023","unstructured":"Robertson S,\nPeacock E,\nScott R. Benzodiazepine use disorder: Common questions and answers. Am Fam Physician. 2023;108:260\u2013266."},{"key":"i-53-2-182-ref07","series-title":"J Subst Abuse Addict Treat","first-page":"209508","article-title":"At the tipping point: Patient experiences of addiction to benzodiazepines and motivation to seek treatment","volume":"167","author":"Burmester","year":"2024","unstructured":"Burmester S,\nKr\u00fcger C,\nFranck J,\nLindberg MH,\nWestman J. At the tipping point: Patient experiences of addiction to benzodiazepines and motivation to seek treatment. J Subst Abuse Addict Treat. 2024;167:209508. doi: 1016\/j.josat.2024.209508"},{"key":"i-53-2-182-ref08","series-title":"Am Fam Physician","first-page":"2121","article-title":"Addiction: Part I. Benzodiazepines \u2013 side effects, abuse risk and alternatives","volume":"61","author":"Longo","year":"2000","unstructured":"Longo LP,\nJohnson B. Addiction: Part I. Benzodiazepines \u2013 side effects, abuse risk and alternatives. Am Fam Physician. 2000;61:2121\u20132128."},{"key":"i-53-2-182-ref09","series-title":"Am Fam Physician","first-page":"2401","article-title":"W. Addiction: Part II. Identification and management of the drug-seeking patient","volume":"61","author":"Longo","year":"2000","unstructured":"Longo LP,\nParran T Jr,\nKinseyJohnson B, W. Addiction: Part II. Identification and management of the drug-seeking patient. Am Fam Physician. 2000;61:2401\u20132408."},{"key":"i-53-2-182-ref10","series-title":"J Psychopharm","article-title":"Incident benzodiazepine and Z-drug use and subsequent risk of alcohol- and drug-related problems: A nationwide matched cohort study with co-twin comparison","author":"Wang","year":"2025","unstructured":"Wang X,\nChang Z,\nMolero Y, et al. Incident benzodiazepine and Z-drug use and subsequent risk of alcohol- and drug-related problems: A nationwide matched cohort study with co-twin comparison. J Psychopharm. 2025:2698811251373069."},{"key":"i-53-2-182-ref11","series-title":"Encephale","first-page":"216","article-title":"Benzodiazepine dependence and the risk of depression and anxiety disorders: seniors; health study","volume":"40","author":"Nkogho Mengue","year":"2014","unstructured":"Nkogho Mengue P-G,\nAbdous B,\nBerbiche D,\nPreville M,\nVoyer P. Benzodiazepine dependence and the risk of depression and anxiety disorders: seniors; health study. Encephale. 2014;40:216\u2013222. doi: 10.1016\/j.encep.2013.04.011"},{"key":"i-53-2-182-ref12","series-title":"Substance Use Misuse","first-page":"1197","article-title":"Factors associated with benzodiazepine misuse among those who misused opioids within the past year: A U.S. national analysis","volume":"60","author":"Ramdin","year":"2025","unstructured":"Ramdin C,\nKalee Mishra K,\nNelson L,\nMeaden C. Factors associated with benzodiazepine misuse among those who misused opioids within the past year: A U.S. national analysis. Substance Use Misuse. 2025;60:1197\u20131203. doi: 10.1080\/108.26084-2025-2494804"}],"container-title":["Journal of Insurance Medicine"],"original-title":[],"link":[{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/53\/2\/article-p182.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/53\/2\/article-p182.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/53\/2\/article-p182.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:30:55Z","timestamp":1783729855000},"score":1,"resource":{"primary":{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/53\/2\/article-p182.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":12,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.17849\/insm-53-2-1-5.1","relation":{},"ISSN":["0743-6661"],"issn-type":[{"value":"0743-6661","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}